RANI

SEC source: 0001104659-23-022702 · tm237124-1_4seq1.xml · nonDerivative · entry 2

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,733,904

F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.08 to $5.25 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-23-022702 · tm237124-1_4seq1.xml · nonDerivative · entry 1

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,723,904

F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.995 to $5.52 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-23-000497 · tm2231865-8_4seq1.xml · nonDerivative · entry 1

Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner

Aequanimitas Limited Partnership · CIK 0001953625 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership

Disclosed balance after: 5,271,378

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.84 to $6.20 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas Limited Partnership ("Aequanimitas") as its general partner with the power to manage Aequanimitas. Quiroga Cortes is the sole limited partner of Aequanimitas.

SEC source: 0001104659-23-000498 · tm2231865-7_4seq1.xml · nonDerivative · entry 2

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,714,654

F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.80 to $6.20 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-23-000498 · tm2231865-7_4seq1.xml · nonDerivative · entry 1

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,706,054

F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.75 to $6.23 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-130920 · tm2231865-6_4seq1.xml · nonDerivative · entry 1

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,697,454

F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.42 to $5.71 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-128587 · tm2232650-4_4seq1.xml · nonDerivative · entry 2

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,688,297

F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.05 to $7.60 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-128587 · tm2232650-4_4seq1.xml · nonDerivative · entry 1

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,681,397

F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.36 to $8.09 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-127821 · tm2231865-5_4seq1.xml · nonDerivative · entry 2

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,674,997

F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.74 to $8.24 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-127821 · tm2231865-5_4seq1.xml · nonDerivative · entry 1

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,668,497

F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.86 to $8.10 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-126906 · tm2232650-2_4seq1.xml · nonDerivative · entry 2

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,658,678

F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.04 to $8.30 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-126906 · tm2232650-2_4seq1.xml · nonDerivative · entry 1

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,646,628

F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.95 to $8.10 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-126159 · tm2231865-4_4seq1.xml · nonDerivative · entry 2

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,634,128

F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.875 to $8.10 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-126159 · tm2231865-4_4seq1.xml · nonDerivative · entry 1

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,621,783

F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.72 to $8.20 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-125384 · tm2231865-3_4seq1.xml · nonDerivative · entry 2

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,609,588

F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.87 to $7.98 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-125384 · tm2231865-3_4seq1.xml · nonDerivative · entry 1

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,608,988

F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.10 to $7.875 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-124794 · tm2231865-2_4seq1.xml · nonDerivative · entry 2

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through Soth Lake One LLC

Disclosed balance after: 6,596,488

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.74 to $8.00 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-124794 · tm2231865-2_4seq1.xml · nonDerivative · entry 1

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,584,293

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.99 to $8.20 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-124012 · tm2231865-1_4seq1.xml · nonDerivative · entry 2

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through Soth Lake One LLC

Disclosed balance after: 6,574,474

F2 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-124012 · tm2231865-1_4seq1.xml · nonDerivative · entry 1

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,574,272

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.785 to $8.00 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-123153 · tm2231288-3_4seq1.xml · nonDerivative · entry 1

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,566,272

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.645 to $8.00 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-122333 · tm2231288-2_4seq1.xml · nonDerivative · entry 2

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,562,552

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.70 to $8.00 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-122333 · tm2231288-2_4seq1.xml · nonDerivative · entry 1

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,561,752

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.55 to $7.99 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

F3 · ownership.nature: South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-121604 · tm2231288-1_4seq1.xml · nonDerivative · entry 3

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,558,356

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.05 to $7.60 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

F4 · ownership.nature: South Cone Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-121604 · tm2231288-1_4seq1.xml · nonDerivative · entry 2

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,545,856

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.00 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

F4 · ownership.nature: South Cone Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-121604 · tm2231288-1_4seq1.xml · nonDerivative · entry 1

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

South Lake One LLC · CIK 0001794292 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 6,542,656

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.39 to $7.82 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

F4 · ownership.nature: South Cone Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.

SEC source: 0001104659-22-115484 · tm2229846-1_4seq1.xml · nonDerivative · entry 1

Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner

Aequanimitas Limited Partnership · CIK 0001953625 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership

Disclosed balance after: 5,262,978

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.42 to $7.00 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas Limited Partnership ("Aequanimitas") as its general partner with the power to manage Aequanimitas. Quiroga Cortes is the sole limited partner of Aequanimitas.

SEC source: 0001104659-22-114089 · tm2229549-1_4seq1.xml · nonDerivative · entry 3

Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership

Disclosed balance after: 5,247,786

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.50 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

F4 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas Limited Partnership ("Aequanimitas") as its general partner with the power to manage Aequanimitas. Quiroga Cortes is the sole limited partner of Aequanimitas.

SEC source: 0001104659-22-115487 · tm2229846-2_4aseq1.xml · nonDerivative · entry 3

Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner

Aequanimitas Limited Partnership · CIK 0001953625 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership

Disclosed balance after: 5,247,786

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.50 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

F1 · ownership.nature: This amendment to Isidoro Alfonso Quiroga Cortes' Form 4, originally filed with the SEC on November 2, 2022 (the "Original Form 4"), is being filed to include Aequanimitas Limited Partnership ("Aequanimitas") as a Reporting Person under the Original Form 4.

F5 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas as its general partner with the power to manage Aequanimitas. Isidoro Alfonso Quiroga Cortes is the sole limited partner of Aequanimitas.

SEC source: 0001104659-22-114089 · tm2229549-1_4seq1.xml · nonDerivative · entry 2

Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership

Disclosed balance after: 5,222,589

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.96 to $6.22 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

F4 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas Limited Partnership ("Aequanimitas") as its general partner with the power to manage Aequanimitas. Quiroga Cortes is the sole limited partner of Aequanimitas.

SEC source: 0001104659-22-115487 · tm2229846-2_4aseq1.xml · nonDerivative · entry 2

Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner

Aequanimitas Limited Partnership · CIK 0001953625 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership

Disclosed balance after: 5,222,589

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.96 to $6.22 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

F1 · ownership.nature: This amendment to Isidoro Alfonso Quiroga Cortes' Form 4, originally filed with the SEC on November 2, 2022 (the "Original Form 4"), is being filed to include Aequanimitas Limited Partnership ("Aequanimitas") as a Reporting Person under the Original Form 4.

F5 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas as its general partner with the power to manage Aequanimitas. Isidoro Alfonso Quiroga Cortes is the sole limited partner of Aequanimitas.

SEC source: 0001104659-22-114089 · tm2229549-1_4seq1.xml · nonDerivative · entry 1

Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership

Disclosed balance after: 5,218,821

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.98 to $6.14 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

F4 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas Limited Partnership ("Aequanimitas") as its general partner with the power to manage Aequanimitas. Quiroga Cortes is the sole limited partner of Aequanimitas.

SEC source: 0001104659-22-115487 · tm2229846-2_4aseq1.xml · nonDerivative · entry 1

Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner

Aequanimitas Limited Partnership · CIK 0001953625 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership

Disclosed balance after: 5,218,821

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.98 to $6.14 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

F1 · ownership.nature: This amendment to Isidoro Alfonso Quiroga Cortes' Form 4, originally filed with the SEC on November 2, 2022 (the "Original Form 4"), is being filed to include Aequanimitas Limited Partnership ("Aequanimitas") as a Reporting Person under the Original Form 4.

F5 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas as its general partner with the power to manage Aequanimitas. Isidoro Alfonso Quiroga Cortes is the sole limited partner of Aequanimitas.

SEC source: 0001209191-22-049800 · doc4.xml · nonDerivative · entry 1

Hashim Mir · CIK 0001875891 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,466

F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on September 9, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the restricted stock units granted to Mr. Hashim on September 9, 2021.

SEC source: 0001209191-22-049802 · doc4.xml · nonDerivative · entry 1

Sanford Svai S · CIK 0001591411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,738

F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on September 9, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the restricted stock units granted to Mr. Sanford on September 9, 2021.

SEC source: 0001209191-22-047661 · doc4.xml · derivative · entry 3

IMRAN MIR A · CIK 0001031686 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 22,660,053

Underlying: Class A Common Stock · 7,694 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F5 · shares: The Reporting Person is a General Partner of Rani Investment Corp. Represents 7,694 LLC Units previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F1 · derivative.exercise_date: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F1 · derivative.expiration_date: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F6 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P., and InCube Labs, LLC is wholly-owned by the Reporting Person and his family. Represents 22,411,124 LLC Units Shares held by InCube Labs, LLC and 248,929 LLC Units held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-047661 · doc4.xml · nonDerivative · entry 2

IMRAN MIR A · CIK 0001031686 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 74,139

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F4 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. InCube Labs, L.L.C. is wholly-owned by the Reporting Person and his family. Represents 52,781 shares of Class A Common Stock of the Issuer held by InCube Ventures II, L.P., 13,664 shares of Class A Common Stock of the Issuer held by InCube Labs, L.L.C., and 7,694 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-047661 · doc4.xml · nonDerivative · entry 1

IMRAN MIR A · CIK 0001031686 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 22,660,053

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F2 · shares: The Reporting Person is a General Partner of Rani Investment Corp. Represents 7,694 Class B Shares previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P., and InCube Labs, LLC is wholly-owned by the Reporting Person and his family. Represents 22,411,124 Class B Shares held by InCube Labs, LLC and 248,929 Class B Shares held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-047662 · doc4.xml · derivative · entry 4

Farquharson Andrew · CIK 0001865699 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 248,929

Underlying: Class A Common Stock · 7,694 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F5 · shares: The Reporting Person is a General Partner of Rani Investment Corp. Represents 7,694 LLC Units previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F1 · derivative.exercise_date: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F1 · derivative.expiration_date: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F6 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. Represents 248,929 LLC Units held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-047662 · doc4.xml · nonDerivative · entry 2

Farquharson Andrew · CIK 0001865699 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 72,818

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F4 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P., VH Moll L.P., and Rani Investment Corp. Represents 52,781 Class A Shares held by InCube Ventures II, L.P, 12,343 Class A Shares held by VH Moll L.P., and 7,694 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-047662 · doc4.xml · nonDerivative · entry 1

Farquharson Andrew · CIK 0001865699 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 248,929

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F2 · shares: The Reporting Person is a General Partner of Rani Investment Corp. Represents 7,694 Class B Shares previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. Represents 248,929 Class B Shares held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-046958 · doc4.xml · nonDerivative · entry 2

IMRAN MIR A · CIK 0001031686 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 66,445

F1 · shares: The Reporting Person is a General Partner of Rani Investment Corp. Represents Class A Shares held by Rani Investment Corp.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.39 to $11.975, inclusive.

F5 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. InCube Labs, L.L.C. is wholly-owned by the Reporting Person and his family. Represents 52,781 shares of Class A Common Stock of the Issuer held by InCube Ventures II, L.P. and 13,664 shares of Class A Common Stock of the Issuer held by InCube Labs, L.L.C. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-046958 · doc4.xml · nonDerivative · entry 1

IMRAN MIR A · CIK 0001031686 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 75,655

F1 · shares: The Reporting Person is a General Partner of Rani Investment Corp. Represents Class A Shares held by Rani Investment Corp.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.39 to $11.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (4) to this Form 4.

F3 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. InCube Labs, L.L.C. is wholly-owned by the Reporting Person and his family. Represents 52,781 shares of Class A Common Stock of the Issuer held by InCube Ventures II, L.P., 13,664 shares of Class A Common Stock of the Issuer held by InCube Labs, L.L.C., and 9,210 shares of Class A Common Stock of the Issuer held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-046957 · doc4.xml · nonDerivative · entry 2

Farquharson Andrew · CIK 0001865699 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 65,124

F1 · shares: The Reporting Person is a General Partner of Rani Investment Corp. Represents Class A Shares held by Rani Investment Corp.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.39 to $11.975, inclusive.

F5 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. and VH Moll, L.P. Represents 52,781 shares of Class A Common Stock of the Issuer held by InCube Ventures II, L.P. and 12,343 shares of Class A Common Stock of the Issuer held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-046957 · doc4.xml · nonDerivative · entry 1

Farquharson Andrew · CIK 0001865699 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 74,334

F1 · shares: The Reporting Person is a General Partner of Rani Investment Corp. Represents Class A Shares held by Rani Investment Corp.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.39 to $11.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (4) to this Form 4.

F3 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P., VH Moll, L.P., and Rani Investment Corp. Represents 52,781 shares of Class A Common Stock of the Issuer held by InCube Ventures II, L.P., 12,343 shares of Class A Common Stock of the Issuer held by VH Moll, L.P., and 9,210 shares of Class A Common Stock of the Issuer held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-22-019853 · doc4.xml · derivative · entry 1

IMRAN MIR A · CIK 0001031686 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,416

Underlying: Class A Common Stock · 41,416 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).

SEC source: 0000899243-22-019855 · doc4.xml · derivative · entry 1

DEBUONO LAUREEN · CIK 0001034447 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,416

Underlying: Class A Common Stock · 41,416 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).

SEC source: 0000899243-22-019859 · doc4.xml · derivative · entry 1

Farquharson Andrew · CIK 0001865699 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,416

Underlying: Class A Common Stock · 41,416 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).

SEC source: 0000899243-22-019857 · doc4.xml · derivative · entry 1

BUTEL JEAN LUC · CIK 0001260801 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,416

Underlying: Class A Common Stock · 41,416 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).

SEC source: 0000899243-22-019860 · doc4.xml · derivative · entry 1

Ausiello Dennis A · CIK 0001381994 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,416

Underlying: Class A Common Stock · 41,416 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).